PFE - Pfizer Inc Stock Price, Fair Value and News

28.01USD-0.17 (-0.60%)Market Closed

Market Summary

USD28.01-0.17

Market Closed

-0.60%

PFE Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

PFE Stock Price

View Fullscreen

PFE RSI Chart

PFE Valuation

Market Cap

159.7B

Price/Earnings (Trailing)

127.44

Price/Sales (Trailing)

2.76

EV/EBITDA

31.65

Price/Free Cashflow

31.29

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

-3.10%

Return on Equity

1.35%

Return on Assets

0.57%

Free Cashflow Yield

3.2%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

57.8B

Rev. Growth (Yr)

310.23%

Rev. Growth (Qtr)

-43.21%

PFE Earnings

Earnings (TTM)

1.3B

Earnings Growth (Yr)

558.56%

Earnings Growth (Qtr)

2.1K%

Breaking Down PFE Revenue

52 Week Range

27.9340.37

(Low)(High)

Last 7 days

1.8%

Last 30 days

5.3%

Last 90 days

2.3%

Trailing 12 Months

-25.6%

How does PFE drawdown profile look like?

PFE Financial Health

Current Ratio

1.05

Debt/Equity

0.66

Debt/Cashflow

0.14

PFE Investor Care

Dividend Yield

5.85%

Dividend/Share (TTM)

1.65

Shares Dilution (1Y)

0.38%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	57.8B	0	0	0
2023	32.7B	33.0B	23.6B	46.5B
2022	49.9B	34.2B	32.8B	32.6B
2021	46.1B	55.1B	68.9B	60.9B
2020	37.9B	34.5B	32.1B	41.7B
2019	41.0B	40.8B	40.2B	40.9B
2018	52.7B	53.2B	53.4B	40.8B
2017	52.6B	52.3B	52.5B	52.5B
2016	51.0B	52.3B	53.2B	52.8B
2015	49.1B	48.2B	47.9B	48.9B
2014	50.5B	50.3B	50.0B	49.6B
2013	52.7B	51.7B	51.4B	51.6B
2012	59.7B	57.1B	53.5B	55.2B
2011	65.1B	64.4B	65.1B	61.3B
2010	55.0B	61.1B	65.5B	65.2B
2009	47.3B	46.2B	45.8B	49.3B
2008	0	48.4B	48.3B	48.3B
2007	0	0	0	48.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Pfizer Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 28, 2024	boshoff christoffel	sold (taxes)	-112,216	27.04	-4,150	executive vice president
Feb 28, 2024	dolsten mikael	sold (taxes)	-579,656	27.04	-21,437	president r&d
Feb 28, 2024	boshoff christoffel	acquired	-	-	11,510	executive vice president
Feb 27, 2024	damico jennifer b.	acquired	-	-	5,113	svp & controller
Feb 27, 2024	de germay alexandre	acquired	-	-	74,377	executive vice president
Feb 26, 2024	mcdermott michael	sold (taxes)	-164,792	27.18	-6,063	executive vice president
Feb 25, 2024	boshoff christoffel	sold (taxes)	-172,029	27.76	-6,197	executive vice president
Feb 25, 2024	boshoff christoffel	acquired	-	-	15,455	executive vice president
Feb 25, 2024	mcdermott michael	sold (taxes)	-83,057	27.76	-2,992	executive vice president
Feb 25, 2024	damico jennifer b.	sold (taxes)	-38,475	27.76	-1,386	svp & controller

Which funds bought or sold PFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	Heritage Wealth Advisors	reduced	-43.49	-222,533	266,202	0.01%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	4.23	84,224,400	260,746,000	0.61%
May 08, 2024	Long Road Investment Counsel, LLC	unchanged	-	5,000	223,000	0.09%
May 08, 2024	Ruffer LLP	added	1.93	-2,989,450	163,848,000	6.31%
May 08, 2024	PRIVATE MANAGEMENT GROUP INC	added	270	531,142	737,578	0.03%
May 08, 2024	STEVENS CAPITAL MANAGEMENT LP	new	-	1,161,000	1,161,000	0.23%
May 08, 2024	TD Asset Management Inc	added	2.81	-624,977	68,849,600	0.06%
May 08, 2024	Hills Bank & Trust Co	reduced	-0.19	-76,810	1,945,020	0.16%
May 08, 2024	COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS	added	0.25	-1,200,980	34,397,600	0.24%
May 08, 2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	reduced	-64.58	-47,724,000	24,743,000	0.07%

Are Funds Buying or Selling PFE?

Are funds buying PFE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PFE

No. of Funds

Unveiling Pfizer Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.97%	506,479,807	SC 13G/A
Jan 29, 2024	state street corp	5.10%	287,875,814	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	434,748,255	SC 13G/A
Feb 09, 2023	vanguard group inc	8.94%	501,636,220	SC 13G/A
Feb 07, 2023	state street corp	5.08%	284,943,697	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	442,868,761	SC 13G/A
Feb 14, 2022	state street corp	5.09%	285,771,591	SC 13G/A
Feb 10, 2022	vanguard group inc	8.29%	465,274,925	SC 13G/A
Feb 01, 2022	blackrock inc.	7.3%	409,985,645	SC 13G/A
Feb 12, 2021	state street corp	5.03%	279,831,373	SC 13G

Recent SEC filings of Pfizer Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	S-8	Employee Benefits Plan
May 08, 2024	10-Q	Quarterly Report
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading

Peers (Alternatives to Pfizer Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.8B	85.6B	-1.57%	-7.27%	9.38	4.21	5.68%	202.39%
MRK	329.8B	61.4B	2.75%	10.43%	143.01	5.37	6.11%	-82.30%
AMGN	167.8B	29.5B	15.72%	33.63%	44.6	5.68	12.76%	-52.47%
PFE	159.7B	57.8B	5.27%	-25.60%	127.44	2.76	76.51%	-86.81%
GILD	80.5B	27.4B	-7.64%	-17.30%	166.11	2.93	1.51%	-91.32%
TEVA	18.1B	16.0B	14.60%	91.74%	-36.67	1.13	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-3.76%	-14.95%	-549.18	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-9.20%	-22.63%	9.45	2.38	54.01%	364.56%
BHC	2.5B	9.0B	-24.84%	16.97%	-5.6	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	3.79%	3.06%	13.41	3.07	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	-4.37%	-28.36%	-4.33	2.05	24.65%	80.36%
TXMD	23.4M	1.3M	-5.58%	-47.55%	-3.16	17.98	-98.14%	-104.71%
ACRX	17.3M	-	-14.29%	43.16%	-0.94	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	5.41%	-93.33%	-0.17	0.13	80.00%	43.08%
ACOR	807.4K	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Pfizer Inc News

Latest updates

Pfizer Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-43.2%	14,879	26,198	13,232	3,490	3,627	3,261	22,638	3,219	3,526	3,420	24,035	18,899	14,516	11,427	10,277	9,864	10,083	1,843	12,680	13,264	13,118
S&GA Expenses	-23.6%	3,495	4,575	3,281	3,497	3,418	4,645	3,391	3,048	2,593	4,104	2,899	2,923	2,777	3,739	2,658	2,659	2,541	2,616	3,260	3,511	3,339
EBITDA Margin	-41.4%	0.12*	0.21*	0.76*	0.91*	1.17*	1.26*	1.22*	1.13*	0.69*	0.51*	0.43*	0.40*	-	-	-	-	-	-	-	-	-
Interest Expenses	-60.9%	415	1,062	332	402	419	321	350	318	453	262	407	353	445	344	387	438	472	341	437	424	385
Income Taxes	136.9%	293	-795	-964	-71.00	715	230	356	1,570	1,172	249	-328	1,123	808	-64.00	-347	422	359	-1,982	3,047	-915	433
Earnings Before Taxes	182.9%	3,421	-4,129	-3,352	2,269	6,270	5,231	9,001	11,447	9,050	3,827	7,843	6,949	5,692	598	570	3,026	2,842	-7,869	10,727	4,141	4,323
EBT Margin	-236.3%	-0.03*	0.02*	0.44*	0.69*	0.98*	1.06*	1.02*	0.94*	0.55*	0.40*	0.31*	0.25*	-	-	-	-	-	-	-	-	-
Net Income	2149.1%	3,115	139	-2,382	382	473	211	8,608	210	468	578	8,146	330	461	221	1,469	518	405	37.00	148	5,046	3,884
Net Income Margin	172.7%	0.02*	-0.03*	-0.06*	0.29*	0.29*	0.29*	0.30*	0.27*	0.19*	0.16*	0.13*	0.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	-90.8%	386	4,196	2,646	-2,122	73.00	7,581	5,133	7,419	5,898	4,912	10,211	10,762	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.4%	221,000	226,501	42,830	220,168	196,000	197,000	41,137	195,290	183,841	181,476	46,335	169,920	158,818	154,229	44,975	44,244	45,840	167,594	46,081	156,199	155,000
Current Assets	-2.1%	42,415	43,333	5,876	73,347	50,078	51,259	5,932	67,466	54,420	59,693	6,890	48,814	39,533	35,067	6,614	7,136	8,213	32,803	7,505	47,073	45,290
Cash Equivalents	-72.7%	780	2,853	3,148	2,632	2,166	416	1,338	1,824	2,513	1,983	2,034	2,418	1,809	1,825	1,627	1,845	2,196	1,350	2,846	1,837	2,018
Inventory	6.9%	10,892	10,189	10,204	10,310	9,541	8,981	9,513	10,454	9,979	9,059	8,640	8,948	8,493	8,020	9,295	8,564	8,423	7,068	8,222	8,233	8,029
Net PPE	-0.7%	18,803	18,940	17,862	17,488	17,052	16,274	15,441	15,244	15,109	14,882	14,436	14,224	14,011	13,745	14,403	14,113	14,040	12,969	13,701	13,521	13,467
Goodwill	2.2%	69,297	67,783	51,527	51,572	51,476	51,375	823	49,891	50,211	49,208	49,489	49,867	49,791	49,556	59,902	58,449	58,502	48,181	58,665	53,352	53,487
Liabilities	-6.3%	128,537	137,213	21,862	120,875	94,381	101,288	22,455	107,821	101,155	104,013	10,351	99,605	89,953	90,756	10,576	10,187	10,677	104,148	10,776	96,274	96,263
Current Liabilities	-15.3%	40,497	47,794	6,117	34,647	36,562	42,138	5,235	47,410	39,268	42,671	5,133	35,664	26,652	25,920	5,246	4,992	5,524	37,304	5,241	32,030	29,423
Long Term Debt	-1.1%	61,307	62,000	61,048	61,356	31,704	32,884	32,629	34,294	35,656	36,000	36,250	35,354	35,347	37,000	49,785	50,529	36,281	35,955	36,044	36,168	35,733
LT Debt, Current	-55.6%	1,001	2,254	2,260	3,565	3,567	2,560	2,566	1,276	260	1,636	2,663	3,687	3,676	2,002	2,149	1,481	337	1,462	2,431	2,139	4,471
LT Debt, Non Current	-100.0%	-	62,000	61,048	61,356	31,704	32,884	32,629	34,294	35,656	36,000	36,250	35,354	35,347	37,000	49,785	50,529	36,281	35,955	36,044	36,168	35,733
Shareholder's Equity	4.0%	92,558	89,014	20,719	99,293	101,236	95,661	18,455	87,469	82,685	77,462	35,705	70,315	68,865	63,473	34,154	64,570	65,341	63,447	35,199	59,924	59,158
Retained Earnings	2.5%	121,318	118,353	126,411	128,796	131,102	125,656	122,967	116,608	111,193	103,394	102,252	96,346	95,158	90,392	100,284	100,203	101,000	97,670	100,113	94,440	93,388
Additional Paid-In Capital	0.4%	92,997	92,631	92,496	92,329	92,153	91,802	91,359	91,183	90,844	90,591	89,973	89,336	89,002	88,674	88,161	87,886	87,680	87,428	87,099	86,963	86,635
Accumulated Depreciation	2.0%	16,362	16,045	15,779	15,554	15,514	15,174	14,931	14,969	15,358	15,074	15,403	15,328	15,105	14,812	16,636	16,889	16,929	16,789	16,728	16,389	16,158
Shares Outstanding	0.2%	5,657	5,643	5,646	5,640	5,634	5,608	5,606	5,605	5,617	5,601	5,597	5,598	-	-	-	-	-	-	-	-	-
Minority Interest	0.7%	276	274	249	274	266	256	227	261	261	262	279	273	245	235	245	138	133	303	105	357	352
Float	-	-	-	-	207,000	-	-	-	294,000	-	-	-	223,000	-	-	-	169,000	-	-	-	241,000	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-79.2%	1,090	5,240	3,456	-1,208	1,212	8,582	5,974	8,170	6,541	5,914	10,829	11,299	4,538	5,625	2,090	3,555	3,133	3,769	4,510	2,611	1,698
Share Based Compensation	81.8%	220	121	151	148	105	364	135	287	86.00	496	293	221	172	287	224	187	57.00	239	64.00	199	185
Cashflow From Investing	115.8%	1,732	-10,996	888	-25,485	3,315	-4,410	-627	-11,313	567	-2,586	-10,076	-8,137	-1,747	8,330	481	-13,011	-71.00	-2,833	-6,760	-1,902	7,550
Cashflow From Financing	-190.6%	-4,931	5,442	-3,779	27,174	-2,771	-5,015	-5,761	2,520	-6,578	-3,351	-1,101	-2,557	-2,807	-13,787	-2,821	9,159	-2,200	-2,440	3,273	-851	-8,467
Buy Backs	-	-	-	-	-	-	-	-	-	2,000	-	-	-	-	-	-	-	-	-	-	-	8,865

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PFE Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions

3 Months Ended

Mar. 31, 2024

Apr. 02, 2023

Alliance revenues

^[1]

$ 2,172

$ 2,060

Total revenues

14,879

18,486

Costs and expenses:

Cost of sales

^[2]

3,379

4,886

Selling, informational and administrative expenses

^[2]

3,495

3,418

Research and development expenses

^[2]

2,493

2,505

Acquired in-process research and development expenses

Amortization of intangible assets

1,308

1,103

Restructuring charges and certain acquisition-related costs

102

Other (income)/deductions––net

680

275

Income from continuing operations before provision/(benefit) for taxes on income

^[3]

3,421

6,270

Provision/(benefit) for taxes on income

293

715

Income from continuing operations

3,128

5,555

Discontinued operations––net of tax

(5)

Net income before allocation to noncontrolling interests

3,123

5,556

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc. common shareholders

$ 3,115

$ 5,543

Earnings per common share––basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.55

$ 0.98

Discontinued operations––net of tax (in dollars per share)

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

0.55

0.98

Earnings per common share––diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

0.55

0.97

Discontinued operations––net of tax (in dollars per share)

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.55

$ 0.97

Weighted-average shares--basic (in shares)

5,657

5,634

Weighted-average shares--diluted (in shares)

5,697

5,727

Product revenues

Revenues

^[1]

$ 12,443

$ 16,221

Royalty revenues

Revenues

^[1]

$ 263

$ 204

[1]	See Note 1A.
[2]	Exclusive of amortization of intangible assets.
[3]	Income from continuing operations before provision/(benefit) for taxes on income. As described above, in connection with the organizational changes effective in the first quarter of 2024, costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations and overhead costs associated with our manufacturing operations are now included in Biopharma’s earnings. We have reclassified $1.4 billion of net costs in the first quarter of 2023 from Other business activities to Biopharma to conform to the current period presentation.

PFE Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions

Mar. 31, 2024

Dec. 31, 2023

Assets

Cash and cash equivalents

$ 719

$ 2,853

Short-term investments

11,209

9,837

Trade accounts receivable, less allowance for doubtful accounts: 2024—$479; 2023—$470

10,989

11,566

Inventories

^[1]

10,892

10,189

Current tax assets

4,233

3,978

Other current assets

4,372

4,911

Total current assets

42,415

43,333

Equity-method investments

8,123

11,637

Long-term investments

3,490

3,731

Property, plant and equipment, less accumulated depreciation: 2024—$16,362; 2023—$16,045

18,803

18,940

Identifiable intangible assets

^[2]

62,829

64,900

Goodwill

^[3]

69,297

67,783

Noncurrent deferred tax assets and other noncurrent tax assets

4,942

3,706

Other noncurrent assets

11,197

12,471

Total assets

221,095

226,501

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2024—$1,001; 2023—$2,254

8,232

10,350

Trade accounts payable

5,591

6,710

Dividends payable

2,372

Income taxes payable

3,192

2,349

Accrued compensation and related items

2,192

2,776

Deferred revenues

2,502

2,700

Other current liabilities

18,788

20,537

Total current liabilities

40,497

47,794

Long-term debt

61,307

61,538

Pension and postretirement benefit obligations

2,076

2,167

Noncurrent deferred tax liabilities

931

640

Other taxes payable

8,603

8,534

Other noncurrent liabilities

15,122

16,539

Total liabilities

128,537

137,213

Commitments and Contingencies

Common stock

480

478

Additional paid-in capital

92,997

92,631

Treasury stock

(114,755)

(114,487)

Retained earnings

121,318

118,353

Accumulated other comprehensive loss

(7,758)

(7,961)

Total Pfizer Inc. shareholders’ equity

92,282

89,014

Equity attributable to noncontrolling interests

276

274

Total equity

92,558

89,288

Total liabilities and equity

$ 221,095

$ 226,501

[1]	The increase from December 31, 2023 reflects higher inventory levels for certain products mainly for supply recovery and network strategy, partially offset by decreases due to net market demand.
[2]	The decrease is primarily due to amortization expense of $1.3 billion and measurement period adjustments related to our acquisition of Seagen of $660 million (see Note 2A).
[3]	All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2024 (see Note 13A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.

About Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

CEO	Dr. Albert Bourla D.V.M., DVM, Ph.D.
WEBSITE	pfizer.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Pfizer Inc Frequently Asked Questions

What is the ticker symbol for Pfizer Inc? What does PFE stand for in stocks?

PFE is the stock ticker symbol of Pfizer Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pfizer Inc (PFE)?

As of Thu May 09 2024, market cap of Pfizer Inc is 159.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers. The fair value of Pfizer Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pfizer Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pfizer Inc a good stock to buy?

The fair value guage provides a quick view whether PFE is over valued or under valued. Whether Pfizer Inc is cheap or expensive depends on the assumptions which impact Pfizer Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PFE.

What is Pfizer Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, PFE's PE ratio (Price to Earnings) is 127.44 and Price to Sales (PS) ratio is 2.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pfizer Inc's stock?

In the past 10 years, Pfizer Inc has provided 0.028 (multiply by 100 for percentage) rate of return.